Literature DB >> 22300137

The PD-1/PD-L1 pathway in human pathology.

M Saresella1, V Rainone, N M Al-Daghri, M Clerici, D Trabattoni.   

Abstract

T-cell activation is dependent on signals delivered through the antigen-specific T-cell receptor and accessory receptors on T-cells. Integration of signals through this family of costimulatory and inhibitory receptors and their ligands regulates the balance between T-cell activation, tolerance, and immunopathology. Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals and exert a vital and diverse range of immunoregulatory roles in T-cell activation, tolerance, and immune-mediated tissue damage. In this review, we revisit current understanding of the immunoregulatory functions of PD-1 and its ligands and their involvement in immune-mediated diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300137     DOI: 10.2174/156652412799218903

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  24 in total

1.  Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions.

Authors:  Louisa Mezache; Cynthia Magro; Craig Hofmeister; Flavia Pichiorri; Douglas Sborov; Gerard J Nuovo
Journal:  Appl Immunohistochem Mol Morphol       Date:  2017-02

2.  Inhibitors of the PD-1/PD-L1 Pathway Can Mobilize the Immune System: An Innovative Potential Therapy for Cancer and Chronic Infections.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2015-04-14       Impact factor: 4.345

3.  Expression and anatomical distribution of TIM-containing molecules in Langerhans cell sarcoma.

Authors:  Jingwei Li; Dayan Cao; Guoning Guo; Yuzhang Wu; Yongwen Chen
Journal:  J Mol Histol       Date:  2012-12-21       Impact factor: 2.611

4.  Discovery of receptor-ligand interfaces in the immunoglobulin superfamily.

Authors:  Nelson Gil; Eduardo J Fajardo; Andras Fiser
Journal:  Proteins       Date:  2019-07-29

5.  89Zr-Labeled Anti-PD-L1 Antibody Fragment for Evaluating In Vivo PD-L1 Levels in Melanoma Mouse Model.

Authors:  Caleb Bridgwater; Anne Geller; Xiaoling Hu; Joe A Burlison; Huang-Ge Zhang; Jun Yan; Haixun Guo
Journal:  Cancer Biother Radiopharm       Date:  2020-04-21       Impact factor: 3.099

6.  Farnesyltransferase inhibitor FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation.

Authors:  W Li; J Tu; X Liu; W Yang
Journal:  Clin Exp Immunol       Date:  2017-07-14       Impact factor: 4.330

7.  Correlation between patients' age and cancer immunotherapy efficacy.

Authors:  Qiong Wu; Qiuhong Wang; Xin Tang; Ran Xu; Luzhong Zhang; Xinming Chen; Qun Xue; Ziheng Wang; Rongfeng Shi; Feiran Wang; Fei Ju; Bo Zhang; You Lang Zhou
Journal:  Oncoimmunology       Date:  2019-02-03       Impact factor: 8.110

8.  PD-L1 is required for human endometrial regenerative cells-associated attenuation of experimental colitis in mice.

Authors:  Ganggang Shi; Grace Wang; Shanzheng Lu; Xiang Li; Baoren Zhang; Xiaoxi Xu; Xu Lan; Yiming Zhao; Hao Wang
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

9.  Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients.

Authors:  Min Deng; Shao-Hua Li; Xu Fu; Xiao-Peng Yan; Jun Chen; Yu-Dong Qiu; Rong-Ping Guo
Journal:  Cancer Cell Int       Date:  2021-07-12       Impact factor: 5.722

10.  Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis.

Authors:  Katherine C Chang; Carey-Ann Burnham; Stephanie M Compton; David P Rasche; Richard J Mazuski; Jacquelyn S McDonough; Jacqueline Unsinger; Alan J Korman; Jonathan M Green; Richard S Hotchkiss
Journal:  Crit Care       Date:  2013-05-11       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.